摘要
目的系统评价奥沙利铂联合吉西他滨(GO方案)治疗晚期非小细胞肺癌(NSCLC)的临床疗效和副作用。方法采用Cochrane系统评价方法进行资料提取、分析、评价。结果共纳入9个研究,520例晚期NSCLC患者,经M eta分析表明,GO方案与吉西他滨+顺铂(GP方案)的近期疗效和远期疗效相近,但GO方案显著降低了胃肠道反应、肾功损害及骨髓抑制。结论奥沙利铂与顺铂治疗晚期NSCLC疗效相似,含奥沙利铂的两药方案耐受性较好,更易为患者接受,可以作为治疗晚期NSCLC化疗方案。
Objective To study the efficiency and toxicities of Oxaliplatin-Gemcitabine combination （ GO regimen） and of cisplatin-gemcitabine combination on advanced non-small cell lung cancer（ NSCLC ）. Methods Search strategy, sample selection, assessment, and data collection and analysis were undertaken by two authors according to the Cochrane handbook for systematic reviews. Results 9 RCTs, including 520 advanced NSCLC patients, were included. Meta-analysis shows that GO regimen has similar therapeutic effect comparing with the GP regimen in beth short term and long term therapy. The toxicity, however, includes gastrointestinal reaction, impaired renal function and bone marrow suppression, is lower in GO regimen. Conclusion The efficiency of response was similar between oxaliplatin and cisplatin. GO regimen is suitable for the treatment of advanced NSCLC.
出处
《实用医院临床杂志》
2009年第2期66-68,共3页
Practical Journal of Clinical Medicine
